Drugs for a new millennium.
A millennium, a century, even a decade is a long time-frame for speculation about anything. Advances in biomedical research in the last few decades have been so extraordinary and escalating at an ever-accelerating pace that any prophecy is a risky proposition. However, it is possible to divine the big, unanswered questions and envisage ways in which they might reasonably be approached in the next few decades, a task which I will try to essay. So many drugs treat so many different medical conditions that a detailed and comprehensive coverage would probably be tiresome. Instead, I will address certain broad themes and diseases that offer both immense challenges and great potential for advances. Rather than review detailed experimental issues, I will confine myself to the 'big picture' issues, providing examples of specific research only in a few instances drawing largely from areas I know best.
Snyder
S H
SH
Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
D000818:Animals; D014150:Antipsychotic Agents; D017209:Apoptosis; D003042:Cocaine; D015195:Drug Design; D013287:Illicit Drugs; D009203:Myocardial Infarction / Q000188:drug therapy; D019253:Proto-Oncogene Proteins c-bcl-2; D012559:Schizophrenia / Q000188:drug therapy; D020521:Stroke / Q000188:drug therapy
D014150:Antipsychotic Agents; D013287:Illicit Drugs; D019253:Proto-Oncogene Proteins c-bcl-2; D003042:Cocaine